Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -6.98
- Piotroski Score 2.00
- Grade Overweight
- Symbol (XGN)
- Company Exagen Inc.
- Price $3.93
- Changes Percentage (-6.45%)
- Change -$0.27
- Day Low $3.85
- Day High $4.83
- Year High $4.83
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/17/2025
- Fiscal Year End N/A
- Average Stock Price Target $5.00
- High Stock Price Target $5.00
- Low Stock Price Target $5.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.09
- Trailing P/E Ratio -1.85
- Forward P/E Ratio -1.85
- P/E Growth -1.85
- Net Income $-23,689,000
Income Statement
Quarterly
Annual
Latest News of XGN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
TX Group's (VTX:TXGN) Returns On Capital Tell Us There Is Reason To Feel Uneasy
As businesses mature, declining Return on Capital Employed (ROCE) and capital employed indicate diminishing shareholder wealth. For TX Group, ROCE is at 2.0%, below the industry average of 9.3%. Despi...
By Yahoo! Finance | 1 week ago -
TX Group's (VTX:TXGN) Earnings Are Weaker Than They Seem
Despite strong earnings, TX Group AG's stock performance was lackluster due to underlying concerns. Unusual gains contributed to profits, but may not be sustainable. Analysts' future profit forecasts ...
By Yahoo! Finance | 2 months ago -
The past three years for AxoGen (NASDAQ:AXGN) investors has not been profitable
Although AxoGen, Inc.'s stock has surged 12% in the last month, long-term returns have been disappointing with a 68% decline over three years. Despite a 9.7% annual revenue growth, the stock price fel...
By Yahoo! Finance | 4 months ago
